13 May 2024

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Annual Report and Notice of Annual General Meeting

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2023 and Notice of Annual General Meeting ("AGM") have today been sent to shareholders.

The Annual Report and Accounts is available on the Investor Relations section of the Company's website https://admedsol.com/Investor-Relations.

The AGM will be held at 11:00 a.m. at the offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QN on 12 June 2024.

A copy of the proxy form for the AGM and Notice of AGM are available on the Company's website https://admedsol.com/investor-relations/shareholder-information/agm.

- End -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made six acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, and Syntacoll, a German specialist in collagen-based absorbable surgical implants.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see  www.admedsol.com.